This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Current guidelines recommend direct-acting oral anticoagulants (DOACs) for AF because they reduce ischemic stroke with a lower risk of brain hemorrhage. By inhibiting Factor XI (an anticoagulation enzyme), drugs like abelacimab potentially prevent thrombosis without increasing spontaneous bleeding risks.
Background:Coronavirus disease 2019 (COVID-19) increases the risk of cerebral venous sinus thrombosis (CVST), and previous reports derived from small case series reported a high mortality in these patients, up to 40%. Median age did not differ between the groups (43 vs 44years,P=0.6)
Both anticoagulants can be used intraoperatively and postoperatively for DVT prophylaxis in patients undergoing subarachnoid hemorrhage (SAH) treatment. Patients from both groups were assessed for baseline clinical characteristics, comorbidities, interventions, complications, and outcomes.
Background:Direct oral anticoagulants (DOACs) are suitable for some patients with cerebral venous thrombosis (CVT). We examined duration of PA prior to DOAC initiation and outcomes in ACTION-CVT, an international retrospective study.Methods:We compared three groups: no lead-in PA, 1-4 days (d) of PA, and 5-21d of PA. 1-4d, 23.8%
Introduction:Seizures are a common initial manifestation of cerebral venous thrombosis (CVT). The primary outcome was delayed seizure(s), occurring after 7 days from CVT diagnosis. The primary outcome was delayed seizure(s), occurring after 7 days from CVT diagnosis. Risk factors included intracranial hemorrhage (OR 2.0
Neutrophil extracellular traps (NETs), associated with poor outcomes and reperfusion resistance, contribute to thrombosis. DNase-I, which degrades neutrophil extracellular traps, could improve thrombolytic efficacy. DNase-I caused no bleeding or impact on HT induced by late tPA.
However, long-term outcomes remain poorly described, and the prognostic significance of the radiographic findings is uncertain.Methods:We extracted demographics and clinical variables for all infants with DMVT at our institution from 2007 to 2023. Stroke, Volume 56, Issue Suppl_1 , Page ATMP85-ATMP85, February 1, 2025.
IntroductionSubarachnoid Hemorrhage (SAH) resulting from the spontaneous rupture of an aneurysm is a rare and highly debilitating condition. The AKI and non‐AKI groups were assessed for baseline clinical characteristics, interventions, complications, and outcomes.
BACKGROUND:Lack of a dedicated thrombectomy device for cerebral venous thrombosis hinders the recanalization ability of endovascular treatment (EVT). The primary efficacy outcome was the proportion of immediate complete recanalization during EVT. Stroke, Volume 56, Issue 1 , Page 5-13, January 1, 2025.
In severe OHSS, increases in capillary permeability can result in hemoconcentration and hypercoagulability leading to thrombotic events, including stroke and cerebral venous thrombosis. The low rate of outcome events after OHSS seen in each of our population-level analyses increases the reliability of these study results.
Primary outcome was modified Rankin scale (mRS) grade at month 3, defined as a good outcome with a mRS2. At month 3, there were no significant differences in the proportion of patients with good outcome (ECP 42.2% Results:In the randomized 189 patients from three hospitals, totally 5 patients were lost to follow-up at month 3.
Bleeds were adjudicated using International Society on Thrombosis and Haemostasis criteria. Patients with intracranial hemorrhage during followup were excluded; those with >1 bleeding event were categorized according to their most severe event. Journal of the American Heart Association, Ahead of Print. versus 60.1%; minor: 32.1%
We therefore aim to characterize the antiplatelet regimens, and associated thromboembolic/hemorrhagicoutcomes, utilized in patients with aneurysms treated with PED Shield.MethodsFactors including demographics, comorbidities, rupture status, devices placed, and antiplatelet regimen, among others, were collected.
The suggested DCV pathophysiologic mechanisms involve vascular inflammation and delayed cerebral thrombosis (DCT). Intra‐arterial and intrathecal vasodilators have been reportedly used with variable outcomes. In our case, we initiated Milrinone for two days, and interestingly, an improvement in the vasospasm was noted (Figure 1).
In light of postoperative CT head showing SAH in the basilar, perimesencephalic, prepontine cisterns, interhemispheric fissure and right frontal sulci as well as intraventricular hemorrhage in fourth ventricle, her presentation was thought to be secondary to cerebral vasospasm in the setting of postoperative SAH.
Blunt cardiac injury my result in : 1) Acute myocardial rupture with tamponade 2) Valve rupture (tricuspid, aortic, mitral) 3) Coronary thrombosis or dissection (and thus Acute MI) from direct coronary blunt injury 4) Dysrhythmias of all kinds. If it had been, could this outcome have been anticipated? And, then, so what?
As a result — cardiac cath was not performed — since results of a cath would not have altered the unfortunate outcome. Widespread ST-depression with reciprocal aVR ST-elevation can be cause by: Heart rate related: tachyarrhythmia (e.g., Initial blood work showed the following: metabolic acidosis on VBG with a lactate of 7.1;
IntroductionThe use of detachable coils for endovascular embolization of cerebral aneurysms has become a safe and effective alternative to direct surgical clipping in patients with ruptured aneurysmal subarachnoid hemorrhage. In order to avoid thromboembolic complications in these cases, patients require treatment with antiplatelet therapy.
Introduction:Exposure to high altitude environment is a risk factor of cerebral venous thrombosis (CVT) probably due to the hypercoagulability. The risk factors, clinical and radiological presentations, treatment, and outcomes were analyzed.Results:A total of 43 patients with CVT from Tibet and 111 patients from PUMCH were included.
The most common cerebrovascular disease complicating bacterial meningitis are cerebral infarctions (9%25%), intracerebral hemorrhage (1%7%), cerebral venous thrombosis (1%10%), and subarachnoid hemorrhage (1%5%).Streptococcus Cerebrovascular complications occur in one fourth of patients with bacterial meningitis.
proposed an innovative thromboembolic stroke model in mice where murine thrombin is injected into the M2 segment of the middle cerebral artery (MCA) to induce arterial thrombosis. We compared the effects of Alteplase in thrombin-model with FeCl3-induced thrombosis model. Introduction:In 2007, Orset et al.
The use of recreational cocaine in young adults is well known to be responsible for acute ischemic and hemorrhagic strokes in individuals who lack other vascular risk factors. Due to the scarcity of these events, the patient outcomes are unclear.
Introduction:COVID-19 infection has thus emerged to be a new risk factor for Cerebral Venous Thrombosis (CVT). Our study aimed to compare outcomes of patients diagnosed with CVT within 2 weeks of COVID infection compared to those without COVID-19.Methods:Adult All-cause mortality was the primary outcome. and three months: 11.6%
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content